Compare PFGC & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PFGC | DVA |
|---|---|---|
| Founded | 1885 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 14.9B |
| IPO Year | 2014 | 2003 |
| Metric | PFGC | DVA |
|---|---|---|
| Price | $111.49 | $235.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $116.44 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.6M | 657.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.26 | ★ 2.87 |
| Revenue | ★ $17,619,900,000.00 | $13,643,069,000.00 |
| Revenue This Year | $15.14 | $3.85 |
| Revenue Next Year | $6.61 | $3.07 |
| P/E Ratio | $87.55 | ★ $81.63 |
| Revenue Growth | 5.12 | ★ 6.46 |
| 52 Week Low | $80.82 | $101.00 |
| 52 Week High | $116.42 | $239.64 |
| Indicator | PFGC | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 65.62 |
| Support Level | $109.77 | $145.58 |
| Resistance Level | $115.63 | $239.64 |
| Average True Range (ATR) | 2.74 | 6.21 |
| MACD | -0.76 | -1.10 |
| Stochastic Oscillator | 36.05 | 79.01 |
Performance Food Group is one of the largest foodservice distributors in the US, with sales of more than $63 billion in fiscal 2025. It sells and distributes food and nonfood products through its foodservice segment, which serves restaurants and institutions, accounting for 53% of sales. PFG also wholesales and distributes products to convenience stores (39%) and through its specialty segment (8% of sales), which serves customers such as vending operators, office coffee service providers, and theaters. The firm's platform spans 250,000 products offered to 300,000 customer locations, supported by 155 distribution centers across all three segments.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.